GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Earnings per Share (Diluted)
中文

Repare Therapeutics (Repare Therapeutics) Earnings per Share (Diluted)

: $-2.23 (TTM As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Repare Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.67. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.23.

Repare Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.23.

Repare Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.67. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.23.

During the past 3 years, the average EPS without NRIGrowth Rate was 5.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.00% per year.

During the past 7 years, Repare Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 16.60% per year. The lowest was -75.80% per year. And the median was -20.75% per year.


Repare Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Repare Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Premium Member Only Premium Member Only -1.17 -2.66 -2.83 -0.69 -2.23

Repare Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.75 -0.83 -0.28 -0.45 -0.67

Competitive Comparison

For the Biotechnology subindustry, Repare Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repare Therapeutics PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's PE Ratio falls into.



Repare Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Repare Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-93.796-0)/42.093
=-2.23

Repare Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-28.03-0)/42.140
=-0.67

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Repare Therapeutics  (NAS:RPTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Repare Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Repare Therapeutics (Repare Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Michael Zinda officer: EVP, Chief Science Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage I, L.p. 10 percent owner ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Repare Therapeutics (Repare Therapeutics) Headlines

From GuruFocus